This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Susanne Hauptlorenz, MD; Bernd Puschendorf, MD
Institute for Medical Chemistry and Biochemistry Marion Wencker

Franz Dienstl, MD
University Clinic for Internal Medicine Innsbruck, Austria

JAMA. 1989;262(21):2996-2997.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor. —

Atrial natriuretic peptide (ANP) is a peptide concerned with the homeostasis of blood volume produced by cardiomyocytes. Atrial stretch, for example in arrhythmias¹ and congestive heart failure,² leads to a release of ANP into the plasma followed by an intracellular and intravascular increase of cyclic 3',5'—guanosine monophosphate (cGMP), its second messenger.³ The question arises whether ANP and cGMP are useful tools to quantify slight congestive heart failure or to control medical therapy. We therefore investigated the ejection fraction and ergometric workload and compared these with the biochemical markers ANP and cGMP. In addition, we studied the influence of β-blockade on these factors.

Study.—

Nine patients who had a myocardial infarction 6 to 8 months previously gave informed consent and entered the study. All patients went through two cycles of 2 weeks' length. The first was a control period, in which all medication except . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?